ABSTRACT
INTRODUCTION: Perivascular epithelioid cell tumors are mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. This type of tumor is rare but bladder localization is even rarer. CASE PRESENTATION: A case of bone metastatic bladder perivascular epithelioid cell tumor in a 65-year-old Caucasian man treated with surgery and chemotherapy is described and compared with other reports in the literature. CONCLUSIONS: The rarity of perivascular epithelioid cell tumors hinders the development of a standard therapeutic approach, and thus requires case report descriptions. There is a need for cooperative studies to enlarge the case series and establish the best treatment strategy for this rare disease.
Subject(s)
Bone Neoplasms/secondary , Ilium , Perivascular Epithelioid Cell Neoplasms/secondary , Urinary Bladder Neoplasms/pathology , Aged , Antimetabolites, Antineoplastic/therapeutic use , Bone Neoplasms/drug therapy , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Humans , Male , Perivascular Epithelioid Cell Neoplasms/drug therapy , Tomography, X-Ray Computed , Urinary Bladder Neoplasms/diagnostic imaging , GemcitabineABSTRACT
AIM: To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer. PATIENTS AND METHODS: Chemotherapy-naive patients with breast cancer were given HEC in an adjuvant or neoadjuvant setting. Palonosetron and dexamethasone 4 mg i.v. were given on day 1 and another two administrations of dexamethasone 4 mg i.m. were given on days 2 and 3. The end-point was complete response (CR) and complete control (CC) during the acute and delayed phases. RESULTS: Twenty-six patients were observed. Complete response was achieved in 19 out of 26 patients (72.4%); the same result was shown in 72.4% out of 76 courses given. CONCLUSION: This alternative schedule suggests efficacy for the control of acute and delayed emesis in moderately emetogenic chemotherapy. Further investigations are required to confirm these results.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Dexamethasone/administration & dosage , Isoquinolines/administration & dosage , Nausea/prevention & control , Quinuclidines/administration & dosage , Vomiting/prevention & control , Adult , Aged , Antineoplastic Agents, Hormonal/administration & dosage , Breast Neoplasms/pathology , Cyclophosphamide/adverse effects , Dose-Response Relationship, Drug , Drug Therapy, Combination , Epirubicin/adverse effects , Female , Fluorouracil/adverse effects , Follow-Up Studies , Humans , Middle Aged , Nausea/chemically induced , Neoplasm Staging , Palonosetron , Prognosis , Serotonin Antagonists/administration & dosage , Vomiting/chemically inducedABSTRACT
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor biology, and patient clinical characteristics, will be one that can maintain quality of life and long-term survival, and even cure selected patients. This review is an overview of the different therapeutic approaches available in metastatic colorectal cancer, for the purpose of defining personalized therapeutic algorithms according to tumor biology and patient clinical features.
